File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients

TitleFirst-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients
Authors
KeywordsHepatitis B
Entecavir
Tenofovir
Hepatitis B core-related antigen
Nucleotide analogue
Issue Date2021
PublisherBioMed Central Ltd. The Journal's web site is located at http://www.biomedcentral.com/bmcgastroenterol/
Citation
BMC Gastroenterology, 2021, v. 21, p. article no. 123 How to Cite?
AbstractBackground: Serum hepatitis B core-related antigen (HBcrAg) is a potential surrogate marker for intra-hepatic covalently-closed circular DNA in chronic hepatitis B (CHB). We aimed to study the profiles of serum HBcrAg in CHB patients treated with first-line nucleos(t)ide analogues (NA): entecavir (ETV), tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF). Method: Serum HBcrAg was measured in 120 treatment-naïve CHB patients receiving one of the 3 NAs (ETV: TDF: TAF = 60: 26: 34) using the Lumipulse G HBcrAg assay in a Lumipulse G1200 analyzer (Fujirebio Inc, Toyko, Japan). Serum HBcrAg levels were measured at week 0, week 48 and week 96 of NA therapy. Results: Among the 120 patients, 67 (55.8%) were hepatitis B e antigen (HBeAg) positive. Both tenofovir and ETV led to significantly lower serum HBcrAg at week 48 and week 96 compared to week 0. There were no significant differences for the magnitude of median HBcrAg decline at week 96 between tenofovir and ETV in HBeAg-positive (2.28 vs. 1.65 log U/mL, p > 0.05) and HBeAg-negative (0.83 vs. 0.54 log U/mL, p > 0.05) patients. TDF and TAF produced no significant differences in the magnitude of median HBcrAg decline at week 96 (HBeAg-positive: 2.63 vs. 1.83, respectively; HBeAg-negative: 1.04 vs. 0.40, respectively; both p > 0.05). Conclusion: Magnitude of reduction of HBcrAg levels after 2-year first-line treatment did not differ statistically among the current first-line NAs, although HBcrAg reduction was numerically greater in tenofovir-treated group. More long-term studies are essential to determine whether tenofovir exerts a more pronounced effect on HBcrAg.
Persistent Identifierhttp://hdl.handle.net/10722/300604
ISSN
2023 Impact Factor: 2.5
2023 SCImago Journal Rankings: 0.747
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMak, LY-
dc.contributor.authorWong, DKH-
dc.contributor.authorCheung, KS-
dc.contributor.authorSeto, WK-
dc.contributor.authorFung, J-
dc.contributor.authorYuen, MF-
dc.date.accessioned2021-06-18T14:54:22Z-
dc.date.available2021-06-18T14:54:22Z-
dc.date.issued2021-
dc.identifier.citationBMC Gastroenterology, 2021, v. 21, p. article no. 123-
dc.identifier.issn1471-230X-
dc.identifier.urihttp://hdl.handle.net/10722/300604-
dc.description.abstractBackground: Serum hepatitis B core-related antigen (HBcrAg) is a potential surrogate marker for intra-hepatic covalently-closed circular DNA in chronic hepatitis B (CHB). We aimed to study the profiles of serum HBcrAg in CHB patients treated with first-line nucleos(t)ide analogues (NA): entecavir (ETV), tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF). Method: Serum HBcrAg was measured in 120 treatment-naïve CHB patients receiving one of the 3 NAs (ETV: TDF: TAF = 60: 26: 34) using the Lumipulse G HBcrAg assay in a Lumipulse G1200 analyzer (Fujirebio Inc, Toyko, Japan). Serum HBcrAg levels were measured at week 0, week 48 and week 96 of NA therapy. Results: Among the 120 patients, 67 (55.8%) were hepatitis B e antigen (HBeAg) positive. Both tenofovir and ETV led to significantly lower serum HBcrAg at week 48 and week 96 compared to week 0. There were no significant differences for the magnitude of median HBcrAg decline at week 96 between tenofovir and ETV in HBeAg-positive (2.28 vs. 1.65 log U/mL, p > 0.05) and HBeAg-negative (0.83 vs. 0.54 log U/mL, p > 0.05) patients. TDF and TAF produced no significant differences in the magnitude of median HBcrAg decline at week 96 (HBeAg-positive: 2.63 vs. 1.83, respectively; HBeAg-negative: 1.04 vs. 0.40, respectively; both p > 0.05). Conclusion: Magnitude of reduction of HBcrAg levels after 2-year first-line treatment did not differ statistically among the current first-line NAs, although HBcrAg reduction was numerically greater in tenofovir-treated group. More long-term studies are essential to determine whether tenofovir exerts a more pronounced effect on HBcrAg.-
dc.languageeng-
dc.publisherBioMed Central Ltd. The Journal's web site is located at http://www.biomedcentral.com/bmcgastroenterol/-
dc.relation.ispartofBMC Gastroenterology-
dc.rightsBMC Gastroenterology. Copyright © BioMed Central Ltd.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectHepatitis B-
dc.subjectEntecavir-
dc.subjectTenofovir-
dc.subjectHepatitis B core-related antigen-
dc.subjectNucleotide analogue-
dc.titleFirst-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients-
dc.typeArticle-
dc.identifier.emailMak, LY: lungyi@hku.hk-
dc.identifier.emailWong, DKH: danywong@hku.hk-
dc.identifier.emailCheung, KS: cks634@hku.hk-
dc.identifier.emailSeto, WK: wkseto@hku.hk-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.authorityMak, LY=rp02668-
dc.identifier.authorityWong, DKH=rp00492-
dc.identifier.authorityCheung, KS=rp02532-
dc.identifier.authoritySeto, WK=rp01659-
dc.identifier.authorityYuen, MF=rp00479-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1186/s12876-021-01711-x-
dc.identifier.pmid33731023-
dc.identifier.pmcidPMC7968194-
dc.identifier.scopuseid_2-s2.0-85102574265-
dc.identifier.hkuros322880-
dc.identifier.volume21-
dc.identifier.spagearticle no. 123-
dc.identifier.epagearticle no. 123-
dc.identifier.isiWOS:000630368300003-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats